Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch Virol ; 164(8): 2171-2173, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31093759

RESUMO

We report here the annotation of the complete genomes of four novel lytic Staphylococcus phages; Stab20, Stab21, Stab22 and Stab23. These phages have double-stranded DNA genomes ranging between 153,338 and 155,962 bp in size with terminal repeats of 10,814-12,304 bp. The genome analysis suggests that they represent new phage species within the genus Kayvirus in the subfamily Twortvirinae of the family Herelleviridae.


Assuntos
Myoviridae/genética , Staphylococcus/genética , DNA Viral/genética , Genoma Viral/genética , Genômica/métodos , Filogenia , Análise de Sequência de DNA/métodos , Fagos de Staphylococcus/genética
2.
J Infect Dev Ctries ; 10(11): 1208-1213, 2016 Nov 24.
Artigo em Inglês | MEDLINE | ID: mdl-27886033

RESUMO

INTRODUCTION: The use of bacteriophages as an alternative treatment method against multidrug-resistant bacteria has not been explored in Kenya. This study sought to determine the efficacy of environmentally obtained lytic bacteriophage against multidrug-resistant Staphylococcus aureus (MDRSA) bacterium in mice. METHODOLOGY: Staphylococcus aureus bacterium and S. aureus-specific lytic phage were isolated from sewage and wastewater collected within Nairobi County, Kenya. Thirty mice were randomly assigned into three groups: MDRSA infection group (n = 20), phage-infection group (n = 5), and non-infection group (n = 5). The MDRSA infection group was further subdivided into three groups: clindamycin treatment (8 mg/kg; n = 5), lytic phage treatment (108 PFU/mL (n = 5), and a combination treatment of clindamycin and lytic phage (n = 5). Treatments were done at either 24 or 72 hours post-infection (p.i), and data on efficacy, bacterial load, and animal physical health were collected. RESULTS: Treatment with phage was more effective (100%) than with clindamycin (62.25% at 24 hours p.i and 87.5% at 72 hours p.i.) or combination treatment (75% at 24 hours p.i. and 90% at 72 hours p.i.) (p < 0.001). CONCLUSIONS: The results show that the environmentally obtained S. aureus lytic bacteriophage has therapeutic potential against MDRSA bacterium in mice.


Assuntos
Terapia Biológica/métodos , Infecções Estafilocócicas/terapia , Fagos de Staphylococcus/crescimento & desenvolvimento , Staphylococcus aureus/virologia , Animais , Antibacterianos/administração & dosagem , Carga Bacteriana , Clindamicina/administração & dosagem , Terapia Combinada , Modelos Animais de Doenças , Farmacorresistência Bacteriana Múltipla , Feminino , Quênia , Masculino , Camundongos Endogâmicos BALB C , Infecções Estafilocócicas/patologia , Fagos de Staphylococcus/isolamento & purificação , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/isolamento & purificação , Análise de Sobrevida , Resultado do Tratamento , Carga Viral , Águas Residuárias/microbiologia , Águas Residuárias/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...